OG-L002
目录号 : GC17314
An LSD1 inhibitor
Cas No.:1357302-64-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Kinase experiment [1]: | |
|
LSD1 demethylation assay |
Human recombinant LSD1 protein is incubated with dimethylated H3K4 peptide as the substrate in the presence of various concentrations of lead compound inhibitors (0 to 75 μM ) or control tranylcypromine. The demethylase activity is measured by the release of H2O2 produced during the catalytic process, using the Amplex red peroxide/peroxidase-coupled assay kit. Each reaction is done in triplicate. The maximum LSD1 demethylase activity is obtained in the absence of inhibitor and corrected for background fluorescence. The Ki (IC50) of OG-L002 is calculated as half-maximal activity. |
| Cell experiment [1]: | |
|
Cell lines |
HeLa, HFF cells, MRC-5 cells |
|
Preparation method |
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
50 μM for 12 hr; |
|
Applications |
OG-L002 inhibited HSV IE gene expression and progeny virus production in both HeLa and HFF cells. |
| Animal experiment [1]: | |
|
Animal models |
Mouse ganglion explant model |
|
Dosage form |
2 to 40 mg/kg /day; intraperitoneal administration for 15-17 days |
|
Applications |
OG-L002 repressed herpes simplex virus (HSV) primary infection in vivo. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: 1Liang, Y., Quenelle, D., Vogel, J. L., Mascaro, C., Ortega, A. and Kristie, T. M. (2013) A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. MBio. 4, e00558-00512 | |
OG-L002 is a specific and potent inhibitor of lysine (K)-specific demethylase 1A (LSD1) with IC50 value of 20 nM [1].
LSD1 is a flavin-dependent monoamine oxidase, which can demethylate lysines. LSD1 plays critical roles in oocyte growth, embryogenesis and tissue-specific differentiation [2].
OG-L002 potently inhibited HSV IE gene expression in both HFF and HeLa cells with IC50 of ~3 μM and ~10 μM, respectively. OG-L002 treatment can potently reduce production of progeny virus (~100-fold) with no significant toxicity in HeLa or HFF cells. In chromatin immunoprecipitation assays, OG-L002 increased the levels of total histone H3K9-me2 and H3 (20- to 30-fold) associated with viral IE promoters, which resulted in decreased viral IE gene expression. In addition, OG-L002 also repressed the expression of adenovirus E1A gene and hCMV IE genes [1].
In a mouse model, OG-L002 repressed primary HSV infection in a dose-dependent manner. Moreover, OG-L002 plays an important role in the viral latency-reactivation cycle in a mouse ganglion explant model [1].
References:
[1]. Liang Y, Quenelle D, Kristie TM, et al. A Novel Selective LSD1/KDM1A Inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. mBio, 2013, 4(1), e00558-12.
[2]. Pedersen MT, Helin K. Histone demethylases in development and disease. Trends in Cell Biology, 2010, 20 (11): 662-71.
| Cas No. | 1357302-64-7 | SDF | |
| 化学名 | 3-[4-[(1R,2S)-2-aminocyclopropyl]phenyl]phenol | ||
| Canonical SMILES | C1C(C1N)C2=CC=C(C=C2)C3=CC(=CC=C3)O | ||
| 分子式 | C15H15NO | 分子量 | 225.29 |
| 溶解度 | ≥ 22.5mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.4387 mL | 22.1936 mL | 44.3872 mL |
| 5 mM | 0.8877 mL | 4.4387 mL | 8.8774 mL |
| 10 mM | 0.4439 mL | 2.2194 mL | 4.4387 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。